Company profile
STRUCTURE THERAPEUTICS INC.
NASDAQ:GPCRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ALENIGLIPRON | phase3 | — | 6 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06703021 | phase2 | completed | 2024-12-20 | 2026-01-12 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity |
| NCT06693843 | phase2 | completed | 2024-10-28 | 2025-10-24 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity |
| NCT07654374 | phase3 | recruiting | 2026-07-17 | 2028-09-01 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) |
| NCT05893043 | phase1 | completed | 2023-04-24 | 2023-06-28 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants |
| NCT06139055 | phase1 | unknown | 2023-10-02 | 2024-03-01 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants |
FDA applications (0)
No records yet.